医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

2019年07月18日 PM09:00
このエントリーをはてなブックマークに追加


 

INGELHEIM, Germany & SEONGNAM, Korea

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.

Both companies will initially focus on developing the compound for the treatment of IPF, an area of high-unmet medical need and one of the key focus areas of Boehringer Ingelheim. Boehringer Ingelheim has developed OFEV® (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and currently approved for the treatment of IPF in more than 70 countries around the world including the US, the EU and Japan.

IPF is a rare, debilitating and fatal lung disease affecting approximately three million people worldwide. It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and breathing difficulties. BBT-877 inhibits autotaxin, an enzyme mediating a key pro-fibrotic event in multiple cell types. It has shown a promising safety and efficacy profile in pre-clinical models for fibrosing interstitial lung diseases and potential for combination with the current standard of care.

Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit said, “We look forward to working with the team at Bridge Biotherapeutics to develop a new treatment option for patients with IPF. This new collaboration complements our growing pipeline in fibrosing interstitial lung diseases and is a sign of our determination to bring the next generation of treatment options to these patients.”

“Bridge Biotherapeutics is pleased to partner with Boehringer Ingelheim, a recognized leader in IPF. The expertise of Boehringer Ingelheim will ensure that our novel therapeutic candidate can be developed to potentially address unmet medical needs of IPF patients worldwide,” said James Lee, CEO of Bridge Biotherapeutics.

“This is a transformational event for Bridge Biotherapeutics with a total potential value in excess of EUR 1.1 billion. It is a testament to the company’s excellence in the development of novel therapeutics for disease areas with high unmet medical need,” commented B. Chris Kim, PhD, a board member of Bridge Biotherapeutics based in Cambridge, Massachusetts.

Bridge Biotherapeutics will receive upfront and near term payments of EUR 45 million and is eligible to receive up to more than EUR 1.1billion in potential payments based upon the successful achievement of specified development, regulatory, and commercial milestones and staggered, up to double digit royalties.

Please click on the link for Notes to Editors:
http://www.boehringer-ingelheim.com/press-release/collaboration-bridge-biotherapeutics

View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005381/en/

CONTACT

Media Contacts

Boehringer Ingelheim

Dr. Reinhard Malin

Head of Communications Innovation Unit

Boehringer Ingelheim Corporate Center GmbH

Media + PR

P: +49 6132 77-90815

reinhard.malin@boehringer-ingelheim.com

Linda Ruckel

Associate Director, Media and Corporate Reputation

Boehringer Ingelheim U.S.

Media + PR

P: + 203-791-6672

linda.ruckel@boehringer-ingelheim.com

Bridge Biotherapeutics, Inc.

Joengbin Ahn

Communications Manager

+82 10-6257-3517

Joengbin.Ahn@bridgebiorx.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024